The non-profit drug developer, Aeras, has signed an agreement with GlaxoSmithKline Vaccines SA to advance the clinical development of a new vaccine against tuberculosis. A Phase 2b trial of the vaccine is scheduled to start in Kenya, India and South Africa.
